1. Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs
- Author
-
Trent E. Balius, Samir Haj-Dahmane, Iwao Ojima, Martin Kaczocha, Jing Sun, Brian P. Ralph, Dale G. Deutsch, William T. Berger, and Robert C. Rizzo
- Subjects
Anti-Inflammatory Agents ,lcsh:Medicine ,Pharmacology ,Biochemistry ,Mice ,chemistry.chemical_compound ,0302 clinical medicine ,Molecular Cell Biology ,Drug Discovery ,lcsh:Science ,Analgesics ,0303 health sciences ,Multidisciplinary ,Drug discovery ,Applied Chemistry ,Neurochemistry ,Biological activity ,Anandamide ,Endocannabinoid system ,3. Good health ,Chemistry ,Medicine ,Neurochemicals ,Synthetic Chemistry ,Fatty Acid-Binding Protein 7 ,Research Article ,Computer Modeling ,Polyunsaturated Alkamides ,medicine.drug_class ,Cognitive Neuroscience ,Immunology ,Pain ,Arachidonic Acids ,Biology ,Fatty Acid-Binding Proteins ,Fatty acid-binding protein ,Anti-inflammatory ,03 medical and health sciences ,medicine ,Animals ,Humans ,030304 developmental biology ,Inflammation ,Tumor Suppressor Proteins ,lcsh:R ,Immunity ,Computational Biology ,Biological Transport ,FABP7 ,Oleic acid ,chemistry ,Computer Science ,Clinical Immunology ,lcsh:Q ,Medicinal Chemistry ,Carrier Proteins ,030217 neurology & neurosurgery ,Endocannabinoids ,Neuroscience - Abstract
Fatty acid binding proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellular transporters for the endocannabinoid anandamide (AEA). Furthermore, animal studies by others have shown that elevated levels of endocannabinoids resulted in beneficial pharmacological effects on stress, pain and inflammation and also ameliorate the effects of drug withdrawal. Based on these observations, we hypothesized that FABP5 and FABP7 would provide excellent pharmacological targets. Thus, we performed a virtual screening of over one million compounds using DOCK and employed a novel footprint similarity scoring function to identify lead compounds with binding profiles similar to oleic acid, a natural FABP substrate. Forty-eight compounds were purchased based on their footprint similarity scores (FPS) and assayed for biological activity against purified human FABP5 employing a fluorescent displacement-binding assay. Four compounds were found to exhibit approximately 50% inhibition or greater at 10 µM, as good as or better inhibitors of FABP5 than BMS309403, a commercially available inhibitor. The most potent inhibitor, γ-truxillic acid 1-naphthyl ester (ChemDiv 8009-2334), was determined to have K(i) value of 1.19±0.01 µM. Accordingly a novel α-truxillic acid 1-naphthyl mono-ester (SB-FI-26) was synthesized and assayed for its inhibitory activity against FABP5, wherein SB-FI-26 exhibited strong binding (K(i) 0.93±0.08 µM). Additionally, we found SB-FI-26 to act as a potent anti-nociceptive agent with mild anti-inflammatory activity in mice, which strongly supports our hypothesis that the inhibition of FABPs and subsequent elevation of anandamide is a promising new approach to drug discovery. Truxillic acids and their derivatives were also shown by others to have anti-inflammatory and anti-nociceptive effects in mice and to be the active component of Chinese a herbal medicine (Incarvillea sinensis) used to treat rheumatism and pain in humans. Our results provide a likely mechanism by which these compounds exert their effects.
- Published
- 2012